Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Fiore Cannabis (CSE:FIOR) signs sale of surplus cannabis licence to fund expansion

Brieanna McCutcheon , The Market Online
0 Comments| February 16, 2021

{{labelSign}}  Favorites
{{errorMessage}}

Fiore Cannabis (FIOR) has signed a non-binding letter of intent on February 15, 2021, to sell–through a wholly-owned subsidiary–a surplus cultivation license for its Apex cannabis cultivation and production facility in Las Vegas, Nevada.

This sale was made possible by Allied Corp. for US$1.5 million.

A definitive agreement is expected to follow within 30 days. Allied is a company actively increasing its involvement in the international medical and specialty cannabis space.

"The licenced sale we are negotiating with Allied pushes us further along our strategic path. We expect to work creatively and effectively with Allied's CEO Calum Hughes and his team to make the licence productive and generate benefits for both companies," said Erik Anderson, President and CEO of Fiore Cannabis.

"Funds from this sale can enable Fiore to speed up the expansion program for our Apex facility to enhance cultivation capacity and deliver additional cannabis products into the growing and high-margin Nevada market," concluded Anderson.

The two companies have developed initial terms that will see them working together as Allied constructs a facility which Fiore would then operate in partnership.

A revenue-sharing agreement for incremental sales from the facility will be negotiated between the parties.

Due to its expertise, Fiore will be assisting with the genetics and selection of cannabis strains for the Allied operation and consulting on the marketing of eventual cannabis products through Fiore's already established medical and retail partnerships.

Fiore plans to apply the proceeds from this sale to its expansion program for the Apex facility. A significant increase in cultivation space is being considered at this time.

Earlier this month, Fiore reported successful crop results in January for the site's current footprint, which was sold immediately into the Nevada retail market.

Fiore Cannabis is a publicly-traded company investing in the development of medical and recreational cannabis products since 2014.

Fiore Cannabis (FIOR) is down 5.88 per cent and is trading at C$0.24 at 12:24 pm EST.



{{labelSign}}  Favorites
{{errorMessage}}


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company